FLOW CYTOMETRY, CD 33

The Flow Cytometry CD33 Test is a specialized immunophenotyping assay used to detect and measure the expression of CD33, a cell surface antigen commonly found on myeloid precursor cells, monocytes, and mature myeloid cells. CD33 is an important marker used in hematology to identify cells of myeloid lineage and plays a significant role in the diagnosis and classification of various blood and bone marrow disorders.

Flow cytometry technology enables rapid analysis of thousands of cells individually, providing detailed information about CD33-positive cell populations. The test is widely used in the evaluation of Acute Myeloid Leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms, and other hematological malignancies involving the myeloid cell line.

CD33 expression helps hematologists determine whether abnormal cells originate from the myeloid lineage and assists in distinguishing AML from lymphoid leukemias. The marker is commonly included in comprehensive leukemia immunophenotyping panels and contributes valuable diagnostic and prognostic information.

Benefits of the Test

• Identifies myeloid cell populations
• Assists in diagnosing Acute Myeloid Leukemia (AML)
• Supports classification of hematological malignancies
• Helps evaluate bone marrow disorders
• Assists disease monitoring and treatment planning
• Provides important immunophenotypic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD33 testing for:

• Suspected Acute Myeloid Leukemia (AML)
• Myelodysplastic syndrome evaluation
• Myeloproliferative neoplasm assessment
• Bone marrow disorder investigation
• Abnormal blood counts
• Leukemia classification studies
• Monitoring hematological malignancies
• Comprehensive flow cytometry panels

The test helps identify abnormal myeloid cell populations and contributes to accurate disease diagnosis.

Preparation Before Test

The test may require:

• Peripheral blood sample
• Bone marrow aspirate
• Body fluid specimen
• Other clinically appropriate samples

Preparation generally includes:

• No fasting is required
• Inform your physician about ongoing medications
• Follow laboratory collection instructions

The sample is processed using advanced multiparameter flow cytometry technology.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on laboratory workflow and testing complexity.

Who Should Take This Test?

• Patients with suspected leukemia
• Individuals with abnormal blood counts
• Patients undergoing bone marrow evaluation
• Individuals with suspected myeloid disorders
• Patients requiring leukemia immunophenotyping
• Individuals referred by hematologists or oncologists

Flow Cytometry CD33 testing is an essential component of modern leukemia diagnostics and bone marrow disorder evaluation.

Clinical Significance

CD33 expression is commonly observed in:

• Acute Myeloid Leukemia (AML)
• Myelodysplastic Syndromes (MDS)
• Myeloproliferative Neoplasms (MPNs)
• Chronic Myeloid Leukemia (CML)
• Monocytic Leukemias
• Myeloid Precursor Cells
• Other Myeloid Malignancies

Abnormal CD33-positive cell populations may indicate myeloid neoplasms and help establish the lineage of leukemic cells.

Important Note

CD33 is usually interpreted together with additional markers such as CD13, CD14, CD15, CD34, CD45, CD64, CD117, HLA-DR, and Myeloperoxidase (MPO). Comprehensive interpretation by a hematopathologist is necessary for accurate diagnosis and clinical management.